Perrigo (PRGO)

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Perrigo Company plc (“Perrigo” or “the Company”) (NYSE: PRGO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Law Offices of Howard G. Smith reminds investors of the upcoming January 16, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”).

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Perrigo Company plc (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”), have until January 16, 2026 to seek appointment as lead plaintiff of the Perrigo class action lawsuit. Captioned French v. Perrigo Company plc, No. 25-cv-09596 (S.D.N.Y.), the Perrigo class action lawsuit charges Perrigo and certain of Perrigo’s top current and former executives with violations of the Securities Exchange Act of 1934.

Glancy Prongay & Murray LLP reminds investors of the upcoming January 16, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”).

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Perrigo Company plc (NYSE: PRGO) securities between February 27, 2024 and November 4, 2025. Perrigo provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Perrigo investors have until January 16, 2025 to file a lead plaintiff motion.

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) between February 27, 2023 and November 4, 2025, inclusive.

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Skye Bioscience, Inc. (NASDAQ:SKYE) and Perrigo Company plc (NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Perrigo Company plc (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”). Perrigo provides over-the-counter health and wellness solutions.

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) between February 27, 2023 and November 4, 2025, inclusive.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Perrigo investors have until January 16, 2025 to file a lead plaintiff motion.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned French v. Perrigo Company plc, et al., Case No. , on behalf of persons and entities that purchased or otherwise acquired Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned French v. Perrigo Company plc, et al., Case No. 1:25-cv-09596, on behalf of persons and entities that purchased or otherwise acquired Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Insiders are buying Bally's, Delcath Systems and Perrigo while their shares are at historic lows and catalysts are ahead.

Stolkholm’s Best Kept Skincare Secret Is The Perfect Gift For Giving

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Palm Beach, FL – July 1, 2021 Astaxanthin may be the most important, potent supplements that most people don’t even know exists.  Astaxanthin is a powerful, naturally occurring carotenoid pigment that’s found in certain marine plants and animals. It is this that causes the pink or red color in salmon, lobster, trout and seafood. Often called “the king of the carotenoids,” Astaxanthin is recognized as being one of the most powerful antioxidants found in nature. Antioxidants are essential for helping combat free radical and oxidative damage to help support a healthy aging process and boost immunity. People take Astaxanthin because of its valuable antioxidant properties. Astaxanthin is 800x stronger than CoQ10, 6,000x stronger than Vitamin C, and 100x stronger than Vitamin E when it comes to antioxidant activity. Astaxanthin helps improve cellular function, and has been linked to improving healthy blood flow, hypertension, improved cardiovascular health, immune health, joint pain, eye health, cognitive alertness and muscle recovery from exercise. Moreover, it has been linked to helping smooth wrinkles, make age spots smaller, and maintain skin moisture.   A report from Market Research Future said that because Astaxanthin is said to have many health values it is projected that the Astaxanthin Market is expected to register a CAGR of 7.7% to reach USD 1,206.52 Million by 2026. “It’s been linked to heart health, endurance, healthier skin, joint pain and may even be applied in future cancer treatment. As a result of this, astaxanthin finds usages in more than a few industries, counting food and beverages, pharmaceuticals, animal feed, and nutraceuticals.”    Active companies in the markets this week include: Pressure BioSciences, Inc. (OTCQB: PBIO), Cyanotech Corporation (NASDAQ: CYAN), Perrigo Company plc (NYSE: PRGO), Medifast (NYSE: MED), Archer-Daniels-Midland Company (NYSE: ADM).